NERVGEN PHARMA CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.1 CAD | -0.47% |
|
0.00% | -22.22% |
| Apr. 17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
| Apr. 17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NERVGEN PHARMA CORP. | Other Biotechnology & Medical Research | -0.47% | 0.00% | -22.22% | +31.25% | +17.98% | 108M | - | - | - |
Technical Rankings Surperformance
- Stock Market
- Equities
- NGEN Stock
- Charts NervGen Pharma Corp.
- Comparison Chart